Interventional Not Pharmacological Study to Investigate the Role of ADA in Multiple Sclerosis PatientsTreated With an Immune-Reconstitution Therapy (2-CdA)

Brief Summary

Detailed Description

The therapeutic landscape for multiple sclerosis (MS) is rapidly evolving. For the past 25 years, there has been an accelerating inclusion of new immunomodulating drugs. MS immunotherapies may also be classified in a different way, into treatments that are given continuously (chronic treatments) and medications that are applied intermittently (immune reconstitution therapies \[IRTs\]). The principle behind the latter is depletion of the immune system that allows it to rebuild itself. An IRT by definition is given at short intermittent courses and not continuously. IRT modalities were shown to induce long-term remission of MS that, in some cases, is close to the definition of a "cure". Most importantly, IRT using these modalities causes substantial changes in the lymphocyte repertoire after the reconstitution phase. This is particularly true for Cladribine (2-CdA), a high efficacy therapy that selectively depletes peripheral lymphocytes, recently approved by the European Medicine Agencies for RMS patients with high activity of disease. Lymphocytes have a high intracellular ratio of DCK to 5'-NTs compared with other cell types. Specifically, levels of DCK and the ratio of DCK to 5'-NT are high in T cells (CD4+ and CD8+), B cells, and dendritic cells but are very low in numerous non-hematologic cell types (http://biogps.gnf.org). This makes lymphocytes, mainly memory B cells, particularly sensitive to the accumulation of 2-CdA nucleotides. The intracellular accumulation of 2-CdATP leads to the incorporation of 2-CdATP into cellular DNA, disrupting the double helix structure and leading to a failure of DNA repair and synthesis. The resulting DNA strand breaks alter the cell cycle progression inducing cell death mediated by apoptosis. Although apoptosis is the most prominent mechanism of action of 2-CdA, additional mechanisms cannot be excluded. Many evidences shown that nucleotide signaling governs some of the most essential responses in immunity, ranging from antigen-driven T lymphocyte proliferation to T helper 1 (Th1) and Th2 cell differentiation, from neutrophil and macrophage chemotaxis to intracellular pathogen killing, and from NADPH-oxidase activation to IL-1β maturation and release. In addition, an analysis of lymphocytes subsets collected in the pivotal phase III trial of Cladribine showed that while T cells reduction shows some Cladribine-dose dependency, B cells have a similar reduction with both dosing schedules in the trial. Moreover, the mean number of T and B cells do not differ between patients remaining free from relapses and patients developing relapses, suggesting that efficacy of Cladribine is not strictly dependent on reduction of lymphocyte count. On the other hand, a lower lymphocyte count has been correlated with a higher risk of developing an Herpes Zoster infection, with all the events restricted and dermatomal, and most of them graded as mild or moderate. Thus, severe lymphopenia is also an important identified risk for safety. In phase III clinical trials (RCTs), 20-25% of the subjects treated with 3.5mg/kg of oral 2-CdA developed transient Grade 3-4 lymphopenia. The rate of patients who discontinued the treatment for lymphopenia was highest (12.4%) in the group that received the greatest cumulative dose of 2-CdA (CC 8.75 mg/kg) at the end of the extension phase of the CLARITY study (22). This effect has been also correlated in others disease with a reduced level of DCK mRNA and a higher level of 5'NT mRNA in lymphocytes. Though the biological activation of 2-CdA needs DCK function independently of ADA action, it cannot be excluded ADA participation in other aspects of 2-CdA mechanism of action, taking in consideration ADA crucial role in lymphocytes activation and function. In line with this, it has been recently identified an ADA genetic variant (rs244072, non-risk/risk allele: T/C) linked to brain inflammation and MS disease severity (article in preparation), by screening more than 50 SNPs in MS-related genes of 514 MS patients and looking for association with clinical and biochemical parameters. The most striking result observed was a direct correlation between the presence of at least one risk allele and EDSS score, namely CT/CC patients show higher values of EDSS than TT patients (p=0.016). Therefore, we hypothesize that the genetic polymorphism of ADA gene, found to correlate with MS disease severity, can also influence the 2-CdA response in term of drug sensitivity/resistance as well as side effects, like lymphocytopenia. According to the rationale, in the panorama of the current therapeutic options available to the patient MRS, Cladribine is the only immune-reconstitution therapy to have an action mechanism that interferes with that of the ADA and for this it has been selected the Cladribine as a reference treatment in clinical practice for this study. Subjects candidate to be treated with Cladribine according to clinical practice and meeting the SmPc requirements during a pre-baseline screening period of up to -3 months before baseline (month 0), will receive an initial treatment course in week 1 and week 5 (W1-W5) as per clinical practice. Subjects will attend visits for blood sample as per mandatory monitoring before initiating Cladribine in year 1, before initiating Cladribine in year 2, and 2 and 6 months after start of treatment in each treatment year. The study will last 2 years for each subjects, providing five visits: screening, at month 0, at month 6, at month 12 and at month 24, according to clinical practice for MS subjects monitoring. The primary objective of the study is to evaluate the influence of the ADA SNP rs244072 (non-risk/risk allele: T/C) on lymphopenia induced by Cladribine (2-CdA) in real world setting in patients with relapsing multiple sclerosis (RMS). The secondary objectives are: * To evaluate molecular, metabolic and immunological factors involved in the mode of action of Cladribine, that can influence patients' response to treatment, focusing in particular on lymphopenia; * To collect safety and tolerability data on RMS patients treated with Cladribine; * To assess the effect of Cladribine on progression of disability and incidence of relapses. The study will include the collection of blood samples to investigate the primary and secondary endpoints. For these analyses, a maximum of 60 ml of blood will be collected at month 0, month 6, month 12 and month 24. Quantitative variables will be reported as mean and standard deviation (SD) or median and Interquartile Range (Q1-Q3), Categorical variables will be reported as number (n) and percentage (%) Primary endpoints and clinical endpoints will be evaluated on all sample. Others secondary endpoint will evaluate on patients of each center unless otherwise indicated. T Student test or Mann Whitney test will be used to compare baseline characteristics of two groups (associated with the genetic polymorphism of ADA), Chi square test o Fisher exact test when necessary, will be used for categorical variables. Shapiro Wilk test and graphics methods will be use to assess normality assumptions. In primary endpoint analysis paired t test will be used to evaluate change in lymphocytes in each group separately. Linear mixed model will be used to compare change in two groups taking in account repetitive data for each patient (patient as random effect) group, time and group per time as fixed effects. Model assumptions will be checked, in case of they are not support logarithm data or other models will be used. Different mixed models will be used to evaluate clinical endpoint on all sample during time. A p value \< 0.05 will be statistically significant.

Primary Outcomes

Secondary Outcomes

• Measure of T cell extracellular acidification rate and mitochondrial respiration(months 0, 6, 12 and 24)
• Evaluation of DCK and 5'NT genes expression(months 0, 6, 12 and 24)
• Statistical correlation of EBV genotypes with responder or non-responder conditions(month 0)
• Genes expression(months 0, 6, 12 and 24)
• Measure of metabolic profile(months 0, 6, 12 and 24)
• Genotyping of SNPs and gene expression for correlation analysis with disease effectiveness of Cladribine treatment(months 0, 6, 12 and 24)
• Blood levels of B-Cell Activating Factor (BAFF) and Proliferating-Inducing Ligand(months 0, 6, 12 and 24)
• Assessment of synaptic alterations induced by T-cell-released cytokines(month 12)
• Assessment of disease progression measuring the change in the Expanded Disability Status Scale (EDSS)/Kurtzke(months 0, 6, 12 and 24)
• Assessment of Kurtzke Functional System Score (KFS) evaluating the type and severity of neurologic impairment(months 0, 6, 12 and 24)
• Evaluation of Disease Activity measuring the Percentage of "No Evidence of Disease Activity" (NEDA) .(months 0, 6, 12 and 24)
• Collection of safety and tolerability data: number of patients with treatment related adverse events classified by MedDRA(months 0, 6, 12 and 24)
• Quantification of DCK and cytosolic forms of NT5 and evaluation of CD4+ enzyme activity(months 0, 6, 12 and 24)
• Assessment of MFI (Mean Fluorescence Intensity) levels in NK, T and B cell subsets(months 0, 6, 12 and 24)
• Assessment of of lower extremity function, performing the Timed 25-Foot Walk test (T25FW)(months 0, 6, 12 and 24)
• Assessment of attention and information processing speed, performing the Symbol Digit Modality Test (SDMT)(months 0, 6, 12 and 24)
• Assessment of upper extremity (arm and hand) function performing the 9-Hole Peg Test (9HPT)(months 0, 6, 12 and 24)
• Evaluation of the change in Annualized Relapse Rate (ARR).(months 0, 6, 12 and 24)